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Abstract: Curcumin has been successfully applied to treat inflammatory conditions in 
experimental research and in clinical trials. The purpose of our study is to evaluate the efficacy 
of an adjunctive-to-traditional treatment with Norflo tablets (curcumin-phosphatidylcholine 
complex; Meriva) administered twice a day in recurrent anterior uveitis of different etiologies. The 
study group consisted of 106 patients who completed a 12-month follow-up therapeutic period. 
We divided the patients into three main groups of different uveitis origin: group 1 (autoimmune 
uveitis), group 2 (herpetic uveitis), and group 3 (different etiologies of uveitis). The primary 
end point of our work was the evaluation of relapse frequency in all treated patients, before 
and after Norflo treatment, followed by the number of relapses in the three etiological groups. 
Wilcoxon signed-rank test showed a P , 0.001 in all groups. The secondary end points were the 
evaluation of relapse severity and of the overall quality of life. The results showed that Norflo 
was well tolerated and could reduce eye discomfort symptoms and signs after a few weeks of 
treatment in more than 80% of patients. In conclusion, our study is the first to report the potential 
therapeutic role of curcumin and its efficacy in eye relapsing diseases, such as anterior uveitis, 
and points out other promising curcumin-related benefits in eye inflammatory and degenerative 
conditions, such as dry eye, maculopathy, glaucoma, and diabetic retinopathy.
Keywords: curcumin, anterior recurrent uveitis, phosphatidylcholine-bound-curcumin (Meriva)
Introduction
In recent clinical studies, curcumin showed its antioxidant, chemopreventive, and anti-
inflammatory activity in acute and chronic inflammation both in clinical   practice (used 
in neurodegenerative, pulmonary, metabolic, autoimmune, and neoplastic   diseases) and 
in experimental models. In the latter case, eg, Mohan et al showed that curcuminoids 
target fibroblast growth factor-2 and inhibit expression of gelatinase B in the angiogenic 
process by using the cultured corneal cells of a transgenic mouse.9 In an experimental 
dry eye model, Chen et al investigated the anti-inflammatory effects of curcumin in 
curcumin pretreated cultured corneal epithelial cells exposed to   hyperosmotic condi-
tions.29 Kumar et al30 reported that curcumin feeding to rats with chemical-induced 
hyperglycemia can reduce oxidative stress that is the main cause of progression of 
cataract.1–12 The beneficial effects of this drug appear now to be related to the effect on 
upregulation of peroxisome proliferator-activated receptor-γ (PPAR-γ), which is a ligand-
inducible transcription factor involved mainly in controlling inflammation in peripheral 
organs. Activation of PPAR-γ  has been shown to control the response in microglial cells 
and limit inflammation.13–17 Curcumin has poor systemic availability, but recent stud-
ies have shown that the phosphatidylcholine formulation (Meriva®) increases its oral Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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bioavailability.18–21 Yadav et al showed the inhibitory effect of 
curcumin on cell proliferation and production of cytokines, 
which are the main phenomena involved in inflammation.12 
Many studies have been conducted on curcumin, but only Lal 
et al have shown the efficacy of curcumin on chronic anterior 
uveitis.22 Based on the previous data, we report our experi-
ence in patients suffering from relapsing anterior uveitis of 
different etiologies.
Material and methods
A total of 122 patients (68 men and 54 women) with recurrent 
anterior uveitis (RAU) were enrolled in the study. The age 
of the patients ranged from 21 to 68 (mean, 37 ± 4.7). All 
patients signed a written informed consent before entering 
into the study in accordance with the Helsinki International 
Treaty criteria. The patients included in the study were 
selected from those followed in our tertiary referral uveitis 
centre (Lavagna Hospital, Genova, Italy) in a previous period 
of about 2 years (mean ± 3 months) and affected by RAU with 
1–4 relapses in a year. The RAU diagnosis was made by two 
different ophthalmologists with more experience on uveitis 
and was based on standard clinical criteria of International 
Uveitis Study Group (IUSG).23 Ophthalmological examina-
tion included each time: slit-lamp examination with IUSG 
grading of anterior segment cells and flare (from 0 to 4+), 
Early Treatment Diabetic Retinopathy Study (ETDRS) visual 
acuity measurement, intraocular pressure measurement, and 
fundus examination with Volk + 90 lens. We developed a 
specific medical record in which, at each check-up visit, we 
registered the findings for each patient included in the study. 
Recurrent anterior bilateral or unilateral uveitis etiology 
was mainly of autoimmune origin (56 patients), followed 
by RAU of herpetic origin (28 patients), and of different or 
unknown origin (22 patients). All the patients received an 
orally administered product, Norflo® (Eye Pharma Co, Italy) 
containing 600 mg of Meriva (Indena, Milano, Italy) in each 
tablet, at the dosage of two tablets/day during the follow-up 
period. An ongoing therapy with systemic drugs (steroids, 
immune-suppressants, antiherpetic, and antitoxoplasmic 
drugs) or eye drops (steroids, mydriatics, and cycloplegics 
nonsteroidal anti-inflammatory drug) was maintained, and 
Norflo tablets were added as an adjunctive treatment. The 
therapy was only administered to patients who had frequent 
relapses in the last 2 years of follow-up and was started at 
the time of a relapse. The follow-up period varied from 12 
to 18 months (mean ± 3 months), and 106 patients (61 men 
and 45 women) completed the study. All patients underwent 
complete ophthalmological examination at 0, 7–15, 30, 90, 
180, and 360 days. The evaluation of the results at the end of 
the follow-up period was carried out by comparing the results 
before and after 1 year of follow-up in patients presenting 
4, 3, 2, or 1 relapses per year. We also studied the percentage 
of satisfaction and tolerance to additional therapy by means 
of a detailed questionnaire (included into the clinical record 
sheet) developed with the purpose of analyzing the patient 
tolerance and compliance to treatment at the end of 1 year 
Norflo therapy.
Statistical analysis
Frequency of total relapses, before and after 1 year of Norflo 
therapy, was assessed with Wilcoxon signed-rank test.
Results
We compared the results, before and after the treatment with 
Norflo, of the total number of patients with relapses and the 
number of total relapses.
As shown in Figure 1A, 106 patients (corresponding 
to the global number of patients included into the study) 
had relapses before the treatment with Norflo, and only 
19 patients had relapses after the treatment with Norflo.
As shown in Figure 1B, there were in total 275 relapses 1 
year before the treatment with Norflo and only 36 relapses at 
the end of the 12-month follow-up period, after the treatment 
with Norflo (88% of improvement).
Tables 1 and 2 show the detailed results before and after 
Norflo treatment in all treated patients, respectively. The table 
specifies the number of patients with 4, 3, 2, or 1 relapses per 
year and the total number of relapses per year.
For instance, in Table 1 (before the treatment with Norflo) 
six patients had four relapses per year, which means a total 
number of 24 relapses per year. In Table 2 (after the treatment 
with Norflo) we can see that no patients had four relapses per 
year, with no relapses in 1 year. Therefore, the six patients 
who had four relapses per year before the treatment had zero 
relapses after Norflo additional therapy. In the second row 
of the same tables, 58 patients had three relapses per year, 
which means a total of 174 relapses before treatment, and 
only four patients had three relapses per year, which means 
a total of 12 relapses per year after treatment.
As shown in the tables, the results were highly significant 
with the Wilcoxon signed-rank test at a P , 0.001 in all 
groups. There was also an improvement in symptoms 
and signs associated with relapses after Norflo treatment, 
including ocular pain, blurring of vision, pericorneal 
hyperemia and aqueous or vitreous cells, and flare in 42% 
of patients. Only seven patients worsened, and they required Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1203
Management of chronic anterior uveitis relapses
degeneration, retinal ischemia, and diabetic retinopathy) 
are now considered from an inflammatory point of view. 
Therefore, the treatment of inflammation could represent an 
important target to manage ocular diseases. Based on these 
observations, conditions that are etiologically far from each 
other converge into the same inflammatory pathway. The ben-
eficial effects of curcumin are suggested by epidemiological 
trials, supported by studies in animal models, and are extrapo-
lated from in vivo studies but are not yet clinically validated, 
because the main disadvantages with curcumin therapy are its 
stability and bioavailability. Curcumin was recently complex-
ated with phospholipids and the obtained product (Meriva) 
showed to improve at least 10 times the bioavailability vs 
uncomplexated curcumin in humans.19–21,24–26
After reviewing several studies on curcumin and on 
curcumin–phosphatidylcholine complex, some dealing on 
its anti-inflammatory effect in eye diseases,13–15,19,22,27–39 we 
decided to demonstrate Norflo efficacy as oral treatment of 
a typical chronic relapsing eye disease as RAU by means 
of a nonplacebo controlled study. It was an adjunct to stan-
dard treatment in 122 patients affected by RAU of different 
etiologies. All these patients completed at least 1 year follow-
up, but 16 patients were excluded from the study; 15 of whom 
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Figure 1 A) Total number of patients with relapses before and after Norflo therapy. B) Total relapse number before and after Norflo therapy.
Note: Wilcoxon signed-rank test: P , 0.001.
Table 1 Results obtained before Norflo treatment
Number of 
patients with 
relapses
Number of relapses  
for each patient  
per year
Relapses per year   
per group of  
patients
6a 4a 24a
58 3 174
35 2 70
7 1 7
106b – 275b
Notes:  asix patients enrolled four relapses each per year. This means that the 
total number of relapses for six patients was 24 in 1 year before Norflo treatment.   
b106  patients  enrolled  had  in  1  year  a  total  of  275  relapses  before  Norflo 
treatment.
Table 2 Results obtained after Norflo treatment
Number of  
patients with 
relapses
Number of relapses  
for each patient  
per year
Relapses per year   
per group of  
patients
0 4 0
4a 3a 12a
9 2 18
6 1 6
19b – 36b
Notes: aFour patients enrolled three relapses each per year. This means that the 
total number of relapses per year for four patients was 12 after Norflo treatment. b19 
patients enrolled had in 1 year a total of 36 relapses after Norflo treatment.
subtenon injections of steroids. Among the first 128 patients 
selected, only one subject had to interrupt therapy because 
of gastric intolerance related to reflux esophagitis. Fifteen 
patients dropped out of the study because of noncompliance 
with therapy or with follow-up visits. At the subjective symp-
toms and compliance questionnaire, 86% patients reported a 
subjective systemic well-being on evaluation progressively 
developed after 4–6 weeks of treatment and full compliance 
at the end of the follow-up period.
Discussion
In a recent review article Jacob et al studied curcumin’s 
mechanism of anti-inflammatory activity both in vitro and 
in vivo preclinical studies. The author proved its beneficial 
anti-inflammatory and antivascular endothelial growth factor 
(VEGF) effects mediated by the upregulation of PPAR-γ 
activation (curcumin is, in fact, a PPAR-γ agonist).3 Immune 
cells mainly participating in ocular inflammation are the ones 
of glia and microglia. These cells, which participate in ocular 
inflammation, are controlled in their functions by PPAR-γ 
action, which acts as a body metabolism sensor.13 Many 
ocular degenerative diseases that were not originally con-
sidered to be inflammatory (glaucoma, age-related macular Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Dovepress
1204
Allegri et al
because of incomplete compliance with our therapeutic regi-
men or follow-up visits and one due to gastric intolerance 
related to reflux esophagitis syndrome. We included in our 
study only the patients followed for at least 2 years in our 
uveitis tertiary care out patient department who were affected 
by chronic relapsing anterior uveitis, which was difficult to 
manage because of high frequency and unpredictability of 
relapses. These subjects suffered from uveitis of different 
etiologies, among which we found three main different etio-
logical groups: herpetic (varicella zoster virus, herpes sim-
plex virus, cytomegalovirus, and Epstein–Barr virus) uveitis, 
autoimmune (sarcoidosis, overlap syndrome, systemic lupus 
erythematosus, and rheumatoid arthritis) inflammatory ocular 
disease, and various origin anterior uveitis (8 unknown origin, 
7 toxoplasmic etiology, 3 tuberculosis, and 4 Lyme disease). 
Among these three groups, the most sensitive patients for 
treatment were autoimmune RAU, and the more relapsing 
patients were herpetic-derived RAU. This might be explained 
by the fact that herpetic uveitis is a mixture of autoimmune 
and viral origin diseases with typically relapsing syndromes. 
A continuous and protracted treatment gave the result of a 
good anti-inflammatory effect and prevention of relapses. In 
fact, in the first treatment period, we observed some relapses 
which disappeared in late, months of treatment. In our study, 
according to Malchiodi-Albedi et al,13 we suppose that the 
therapeutic efficacy of PPAR-γ ligands is showed by the 
suppression and the improvement of clinical symptoms and 
decrease of clinical signs. From the point of view of side 
effects, we report only one patient who dropped out because 
of a gastric intolerance to curcumin tablets not reported in 
literature (we found only reports on curcumin-induced aller-
gic contact dermatitis).31,32 The conclusion of our experience 
is that we can define curcumin as a bioactive, well-tolerated, 
and nontoxic therapy.
In the literature there is only one previous study on 
chronic anterior uveitis and curcumin treatment. It is a small 
study in which curcumin was orally administered at the daily 
dosage of 1.125 mg to 36 patients who were divided into 
two groups: curcumin tablets and topical anti-inflammatory 
therapy and previous treatment plus anti-tuberculosis treat-
ment. The results shown in this study were surprisingly 
favorable to curcumin-alone treated subjects. The researchers 
explained this important result by assuming that curcumin 
is as effective as the corticosteroid therapy, but without any 
evidence of side-effects.22
Our work showed for the first time that Meriva formula-
tion permits us to reach active therapeutic levels in the eye 
at a common dosage of two tablets/day and is well tolerated. 
Indeed, about 90% of the selected patients completed the 
1 year follow-up. The success of our work suggests that 
curcumin’s potential anti-inflammatory effect may be useful 
in other chronic or relapsing ocular surface diseases, such 
as dry eye syndrome, allergic conjunctivitis, and blepharitis. 
Chen et al investigated the anti-inflammatory efficacy of 
curcumin in treating in vitro dry eye syndrome model and 
concluded that curcumin has a potential therapeutic effect for 
treating this disease.29,30 Moreover, curcumin’s therapeutic use 
in addition to traditional therapeutic protocols may be use-
ful in retinal inflammatory diseases, such as macular edema 
or in retinal neovascular proliferative diseases, because 
curcumin is shown also to modulate angiogenesis. Uncon-
trolled angiogenesis had been associated with pathological 
eye conditions, such as diabetic retinopathy and choroidal or 
retinal neovascularization related to VEGF’s effect.14,15,19,40–42 
In fact, curcumin has been shown to prevent choroidal and 
retinal neovascularization in several experimental animal 
models, notably through the inhibition of VEGF receptor 
expression.15
Our trial has the main limit of a nonplacebo-controlled 
study, although we compared for statistical analysis a group of 
frequently recurring uveitis patients studied for 2 years before 
treatment and 1 year after treatment, who may be considered in 
the period before Norflo treatment as a control group, because 
we only add curcumin to previous standard therapy.
Another limit is the lack of standard measurements of 
anterior chamber inflammation by means of a laser cell flare 
meter, but the new instrument, actually available in com-
merce, has some structural defects which do not allow in all 
cases, a true value of intraocular inflammation in the case 
of small pupils because of synechiae and of opacities of the 
lens, which are typical of RAU.
Conclusion
Turmeric has been used for centuries to treat a lot of diseases 
including inflammatory diseases. The supplementation with 
curcumin, its active ingredient, has been shown to be safe 
in humans. The mechanism by which curcumin induces its 
anti-inflammatory effects is yet to be fully elucidated, but 
many studies have shown its relevance as a potent anti-
inflammatory and immuno-modulating agent. PPAR-γ ago-
nists (like curcumin) act on microglia and immune system 
cells modulating both innate and adaptive immune responses, 
and can have a profound effect on the inflammatory cascade. 
The positive results of our study show that Norflo (curcumin-
phosphatidylcholine complex) can play an important role 
in the adjunctive therapy of RAU of various origins and Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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gives a contribution to the clinical potential efficacy of this 
plant-derived product in medicine.
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